Editas medicine stock price.

Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...

Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.

DraftKings (NASDAQ:DKNG) was upgraded to Buy from Neutral at MoffettNathanson, with its price target raised by $6.00 to $37.00. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to …

Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.81% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.06 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $13.94 and as low as $6.08. Year to date, Editas ...All three healthcare stocks are showing solid long-term potential. ... Editas Medicine is focusing on a gene therapy EDIT-301 for rare blood disorders. ... Price as of November 30, 2023, 4:00 p.m ...Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This compares to a market capitalization of ...Aug 7, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...

Editas Medicine is a CRISPR company based out of Cambridge, Massachusetts, working "to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines " At the ...

Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...

Editas Medicine is forecast to grow earnings and revenue by 0.04% and 51.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be -133.7% in 3 years.May-11-23 10:32AM. Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress. (GlobeNewswire) May-10-23 06:02AM. Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%. (Simply Wall St.)Oct 15, 2020 · The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD. See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.

What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.

Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.What happened. Shares of Editas Medicine ( EDIT 2.28%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday ...

It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...Apr 3, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... EDIT Stock 12 Months Forecast. $12.60. (43.51% Upside) Based on 12 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $12.60 with a high forecast of $19.00 and a low forecast of $7.00. The average price target represents a 43.51% change from the last price of $8.78.View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Nov 21, 2023 · Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $). Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ...

Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.

Get the LIVE share price of Editas Medicine Inc(EDIT) and stock performance in one place to strengthen your trading strategy in US stocks. Now Start Investing in Editas Medicine Inc on Groww. Editas Medicine Inc. Healthcare. $10.77 +0.24(2.28%) 1D. 1D. 1W. 1M. 1Y. 3Y. 5Y. Performance. Open Price: Prev. Close: Volume: Avg. Volume: …

3 Nov 2023 ... ... Editas Medicine's financial status. The company holds a market cap of 684.13M USD, reflecting its size in terms of market value. The price ...Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... Conference Call The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the first quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas …Select an options expiration date from the drop-down list at the top of the table, and select "Near-the-Money" or "Show All' to view all options. Note: Option ...Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …

By contrast, Bluebird and Editas shares both fell by over 50% over the first six months of 2022, while CRISPR's stock price stumbled by a noteworthy 20% during the first half of the year. Image ...Robinhood (HOOD 5.91%), in particular, makes this process a breeze with its stock slices option (useful for weighting) and commission-free trading. Put simply, you …Editas Medicine stock price target cut to $35 from $80 at Truist Nov. 18, 2022 at 7:08 a.m. ET by Tomi Kilgore Editas Medicine started at neutral with $18 stock price target at …Instagram:https://instagram. acp stock dividendbarron's top 100gminnuuu Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences.Price as of December 1, 2023, 4:00 p.m. ET ... Shares of Editas Medicine (EDIT 2.28%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake ... which is the best option trading platformbkti If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti... bmtx Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ...Current Price. $10.58. ... Editas Medicine ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street ...